Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is clearly on the way. The world seems to be spinning faster suddenly, does it not? Well, in such moments, there is only one thing to do — brew a cup of stimulation. Not that we need any help staying awake right now, but why not get an extra edge, yes? On that note, time to dig in to the to-do list and get cracking. As for you, here are some tidbits to help on your own journey. Hope all goes well today and you stay healthy.

The Bill & Melinda Gates Foundation, along with the Wellcome research charity and Mastercard, are launching a $125 million effort to speed drug development to treat the novel coronavirus, STAT writes. The initiative, the Covid-19 Therapeutics Accelerator, will not be enough to develop a single new medicine by itself, but can jump-start the process. The plan is to provide funds to as many as two dozen companies and academic researchers immediately, before government funding will be available.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.